Immunotherapy and Emerging Cancer Therapies

Further sessions may explore checkpoint inhibition in cervical and endometrial cancer, tumour-infiltrating lymphocyte therapy, CAR-T and bispecific antibodies, and oncolytic viruses under investigation for solid tumours. Presentations will examine neoantigen and therapeutic HPV vaccines, adoptive cell transfer, and microbiome-based strategies that shape treatment response. Researchers will discuss predictive biomarkers such as mismatch repair status and PD-L1 expression, alongside mechanisms of primary and acquired resistance. Attention will be given to immune-related adverse events affecting the bowel, thyroid, lungs, and heart, and to the safe use of steroids and immunosuppression. Trial designs including basket, umbrella, and platform studies will be reviewed. Cost, access, and long-term safety monitoring will also be emphasised.

 

 

    Related Conference of Immunotherapy and Emerging Cancer Therapies

    October 05-06, 2026

    22nd International Conference on Cancer Research

    Madrid, Spain
    November 19-20, 2026

    44th World Cancer Conference

    Dubai, UAE
    November 23-24, 2026

    7th Cancer Diagnostics & Treatment Conference

    Miami, USA
    November 23-24, 2026

    8th International Conference on Women Oncology

    Miami, USA
    November 24-25, 2026

    6th International Conference on Oncology and Cancer

    Paris, France
    December 03-04, 2026

    10th Global Meeting on Oncology and Radiology

    Madrid, Spain
    December 08-09, 2026

    27th World Congress on Cancer Summit

    Paris, France
    December 08-09, 2026

    14th Euro Breast Cancer and Therapeutics

    Paris, France
    February 15-16, 2027

    5th World Congress on Oral Cancer

    Singapore City, Singapore
    April 15-16, 2027

    12th World Conference on Breast and Cervical Cancer

    Amsterdam, Netherlands

    Immunotherapy and Emerging Cancer Therapies Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in